CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update [Yahoo! Finance]
CureVac N.V. - Ordinary Shares (CVAC)
Company Research
Source: Yahoo! Finance
Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areas Invoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreement Dosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMO Strengthening of Supervisory Board with appointment of innovation expert Birgit Hoffman and clinical oncologist Mehdi Shahidi, M.D. Chief Financial Officer, Pierre Kemula, to step down at the end of his term October 31, 2024; search for a replacement ongoing with transition plan in place Cash and cash equivalents position of €202.5 million as of June 30, 2024, not including €400 million upfront payment from GSK agreement; reaffirming cash runway into 2028 TÜBINGEN,
Show less
Read more
Impact Snapshot
Event Time:
CVAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVAC alerts
High impacting CureVac N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CVAC
News
- CureVac (NASDAQ: CVAC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $16.00 price target on the stock.MarketBeat
- CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress Accesswire
- CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program [Yahoo! Finance]Yahoo! Finance
- CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine ProgramAccesswire
- CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 CongressAccesswire
CVAC
Sec Filings
- 9/27/24 - Form 144
- 9/25/24 - Form 144
- 9/13/24 - Form 6-K
- CVAC's page on the SEC website